anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hypospadias repair is a complicated surgery even in the best of hands. To date, there is a lack of consensus on which surgical technique offers more favourable post-operative outcomes. The present work was undertaken to evaluate and compare the outcomes and complications rates of two single-stage techniques widely used to repair primary anterior hypospadias, namely Thiersch-Duplay Tubularized Plate Urethroplasty and Koff Urethral Mobilisation and Advancement.
MATERIALS AND METHODS: Data from the medical records of 120 patients operated on for primary anterior hypospadias were retrospectively analysed and compared. The patients were divided into two groups: 60 patients underwent Thiersch-Duplay procedure (Group A) and 60 patients underwent Koff procedure (Group B). They were compared using the Chi-squared or Fisher's exact test to assess the relationship between the adopted surgical technique and the complications' development with a P < 0.05.
RESULTS: Neither intraoperative complications nor acute post-operative complications occurred, whereas 28.3% ( n = 34/120) cases have exhibited at least one late post-operative surgical complication, including 38.3% ( n = 23/60) in Group A and 18.3% ( n = 11/60) in Group B, revealing a better outcome of the Koff procedure despite the statistical insignificance ( P = 0.102). We did not objectify any other complication besides meatal stenosis (MS), urethro-cutaneous fistula (UCF) and wound dehiscence.
CONCLUSION: Overall, our study could not demonstrate the superiority of one technique above another. At the same time, it established the versatility, satisfactory cosmetic and functional results, low MS and UCF rates of Koff urethral mobilization and advancement technique in primary anterior hypospadias repair.
OBJECTIVES: I. Compare the progression-free and overall survival of patients with relapsed or refractory, CD20 expressing, aggressive, B-cell non-Hodgkin's lymphoma treated with ifosfamide, carboplatin, and etoposide with or without rituximab. II. Compare the unconfirmed response rate of patients treated with these regimens. III. Determine the toxicity of ifosfamide, carboplatin, and etoposide with rituximab in these patients.

OUTLINE: This is a randomized study. Patients are stratified according to histology (large B-cell vs other) and risk group (low/low-intermediate vs high-intermediate/high). Patients are randomized to one of two treatment arms. Arm I: Patients receive etoposide IV over 1 hour on days 1-3, carboplatin IV over 1 hour on day 2, ifosfamide IV continuously for 24 hours on day 2, and filgrastim (G-CSF) subcutaneously (SC) on days 5-12. Treatment continues every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive rituximab IV on day 1, etoposide IV over 1 hour on days 2-4, carboplatin IV over 1 hour on day 3, ifosfamide IV continuously for 24 hours on day 3, and G-CSF SC on days 6-13. Patients also receive rituximab IV on day 8 of course 1. Treatment continues every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually for 5 years.

PROJECTED ACCRUAL: A total of 376 patients (188 per arm) will be accrued for this study within 3 years.
The present application relates to nanoemulsion compositions of taxane drugs targeting cancer cells and cancer stem cells and methods of use thereof. A composition of omega-3 polyunsaturated fatty acid (PUFA) -taxane conjugates encapsulated in an oil-in-water Nanoemulsion (NE) drug delivery system. A method of treating cancer by administering to a subject in need of treatment an effective amount of a pharmaceutical composition comprising a PUFA-taxane conjugate encapsulated in an oil-in-water NE drug delivery system and treating cancer. A method of overcoming multidrug resistance by exposing multidrug resistant cells to an effective amount of a pharmaceutical composition comprising an omega-3 polyunsaturated fatty acid (PUFA) -taxane conjugate encapsulated in an oil-in-water NE drug delivery system and inducing death of the multidrug resistant cells. A method for eliminating cancer stem cells. Methods for reducing stem cell activity of cancer stem cells, retaining drugs in vivo, and providing slower release profiles.
Participants randomized to this condition will receive treatment immediately, facilitated by two study staff members, and which consists of two preparatory sessions, followed by the first dosing session and two integration sessions, then the second dosing session and two integration sessions. This is followed by follow-up and long-term follow-up visits up to 12 months post-second dose.
Participants in the Experimental Group will attend an implementation program guided by the Self-Determination Theory (SDT). The 12-week intervention consists of a 4-week, group-based, face-to-face supervised sessions conducted by a well-trained Research Assistant, plus an 8-week self-management phase.
Personal care compositions comprising responsive particles. In one aspect, the responsive particle comprises: (1) a particle core having an interfacial surface, (2) a first polymer having a first property, and (3) a second polymer having a contrasting property. The first polymer and the second polymer are attached at different locations to the interfacial surface of the particle core. In another aspect, the responsive particle comprises: (1) a particle core having an interfacial surface, (2) at least one block co-polymer comprising a first block and a second block, wherein said first block has a first property and said second block has a second property, and (3) optionally, at least one other polymer having a third property.; The block co-polymer and the optional other polymer (if present) are attached to the interfacial surface of the particle core, and at least one of the properties contrasts. The personal care compositions also comprise a dermatologically acceptable carrier. Also disclosed are methods of making responsive particles.
Hyperlipidemia plays important roles in the development and progression of atherosclerosis. Modulating lipid levels has been shown to reduce the development of atherosclerosis and incidence of cardiovascular disease. The HMG-CoA reductase inhibitors (also known as statins) are the most effective agents available in the management of hyperlipidemia and prevention of major cardiovascular events. Although statin based therapy is commonplace in primary and secondary prevention, several economical, clinical and safety issues have been raised, so that there is ongoing research into new, safer and more effective agents to be used alone or in combination with existing cardiovascular drugs.

Coenzyme A (CoA) is a ubiquitous essential cofactor that plays a central role in the metabolism of carboxylic acids, including short- and long-chain fatty acids, as well as carbohydrate and protein. In the metabolic pathway of lipid, CoA participates in fatty acid β-oxidation, promoting triglyceride (TG) catabolism. Previous research revealed that insufficiency of CoA in vivo influenced fatty acid β-oxidation catabolism and impaired clearance of TG from plasma, which was supposed to be one plausible reason resulting in type Ⅱb and Ⅳ hyperlipoproteinemia. In addition, epidemiological studies showed the prevalence of serum lipids level increased with age, which may be related to the reduction of CoA synthesis in aging individuals. Moreover, studies on animals have given evidence to prove that supplement of CoA had normalizing activity on plasma lipids in dyslipidemia.

Pantethine is a versatile and very well tolerated hypolipidemic agent that can decrease serum triglycerides, LDL cholesterol, and apolipoprotein B, while increasing HDL cholesterol and apolipoprotein A-I. Pantethine is the disulfide of pantetheine which per se occurs naturally as a product of coenzyme A catabolism. Theoretically, antihyperlipidemia effect of CoA should be more directly and effectively than pantethine. Researches on rabbits and rats models prove that high dose CoA orally can relieve fasting hyperlipidemia and insulin resistance induced by high fat diet. So far there has not been sufficient clinical research data to support the efficacy of CoA in dyslipidemia patients. The present study compares the safety and effectiveness of oral CoA and Pantetheine.
Apparatus, systems, and methods to capture and combine patient vitals and image data are disclosed. An example apparatus includes at least one of video capturing device or an audio receiving device, a vitals data manager, and a vitals aggregator. The video capturing device is to capture visual vital information of a patient from a vital monitor during an imaging procedure. The audio receiving device is to capture audible vital information of the patient during the imaging procedure. The vitals data manager is to receive at least one of the captured visual vital information or the captured audible vital information, the at least one of the captured visual vital information or the captured audible vital information to be tagged with an identifier of the patient to form tagged vitals information. The vitals aggregator is to receive the tagged vitals information and the image associated with the patient, the vitals aggregator to organize the tagged vitals information with the image associated with the patient to form a composite image.
BACKGROUND: Bilateral duplicated kidney and ureter is a rare condition in urology, and it is even rarer for patients to have multiple stones simultaneously. We delineate the diagnostic and therapeutic trajectory of a patient presenting with bilateral duplex kidneys and ureters, characterized by the presence of multiple stones. Notably, the left kidney is a complete duplication, whereas the right kidney exhibits an incomplete duplication.
CASE PRESENTATION: A 47-year-old male patient was diagnosed with bilateral duplex kidney and ureter combined with multiple stones. Ureteral flexible lithotripsy and percutaneous nephrolithotomy were performed successively in our hospital. On the postoperative five day, he was discharged from the hospital without apparent discomfort.The double J tube was pulled out one month later, and no stone recurrence was found after 3 months of follow-up.
CONCLUSIONS: Bilateral duplicated renal ureteral malformations combined with multiple stones are very rare. Stones can be removed by ureteroscopic lithotripsy or percutaneous nephrolithotripsy and sometimes multiple procedures are required, which should be chosen according to the patient's relevant condition.
see and The combination of promethazine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age, because the combination may cause fatal respiratory depression in this age population (WARNINGS – Box Warning). Use In Pediatric Patients

Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme CYP2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine. Codeine is contraindicated for post-operative pain management in these patients (see and ). WARNINGS - Death Related to Ultra-Rapid Metabolism of Codeine toMorphineCONTRAINDICATIONS

The combination of promethazine hydrochloride and codeine phosphate should be used with caution in pediatric patients 6 years and older (see ). WARNINGS-Use in Pediatric Patients
1467739 1,1-Dialkyl-alkylamines and precursors LABAZ 15 May 1975 [20 May 1974] 20738/75 Heading C2C [Also in Division A5] Compounds of formula 'wherein R 1  and B 3  are H or alkyl, alkenyl or alkynyl of up to 6 C atoms and R 2  is C 2 -C 7  alkyl, alkenyl or alkynyl, other than CH= CHR 4  or C#CR 4  (wherein R 4  is H or C 1 -C 5  alkyl), and the total number of carbon atoms in R 1 , R 2  and R 3  is not more than 13, are prepared by treating an isocyanate or formamide of the general formula wherein A is -N=C=O or -NHCHO, with a strong acid and treating the resulting acid addition salt with a base. The resulting free base may be reacted with an acid to form a pharmaceutically acceptable salt. Compounds of Formula I wherein R 1  and R 3  are C 1 -C 3  alkyl or C 2 -C 3  alkenyl or alkynyl and R 2  is -CH 2 -R 5 , wherein R 1 , R 3  and R 5  are identical, can also be prepared by heating, in an anhydrous ether, a nitrate of formula with an organo-magnesium compound of formula wherein X is Cl, Br or I, and hydrolysing the complex thus formed. Compounds of Formula I wherein R and R 3 , are H or C 1 -C 6  alkyl and R 2  is ethynyl may be prepared by reacting sodamide with a compound of Formula wherein Hal is Cl or Br. Compounds of Formula I wherein R 1  and R 3  or C 1 -C 6  alkyl and R 2  is a radical of formula -C#CR 4  (wherein R 4  is C 1 -C 5  alkyl) are prepared by reacting a compound of formula wherein Me is alkali metal, with a halide of formula wherein Hal is Cl or Br. Compounds of Formula I wherein R 1  and R 3  are H or C 1 -C 6  alkyl and R 2  is alkenyl of formula -CH=CHR 4  (wherein R 4  is H or C 1 -C 5  alkyl) are prepared by hydrogenating in an appropriate solvent, and in the presence of a Lindlar catalyst, a compound of formula Isocyanates (II) are prepared (a) by reacting an amide of formula with chlorine or bromine in an alkaline medium, or (b) by reacting an acid of formula with a chlorinating agent such as thionyl chloride or oxalyl chloride, to obtain the corresponding acyl chloride, which is then treated with a metal azide, or by heating a compound of Formula (X) with hydrogen azide in an acid medium; the isocyanate thus formed being hydrolysed immediately to the corresponding amine. Formamides (II) are prepared by heating an alcohol of formula with an alkali metal cyanide in the presence of an acid. Amides (IX) may be prepared by reacting anhydrous ammonia with acids of Formula X or with the halides thereof. Acids (X) may be prepared by reacting alcohols (XI) with formic acid in a sulphuric acid medium. Alcohols (XI) may be prepared by reacting an organo-lithium compound with an appropriate ketone in an anhydrous ether medium. Halides (V) may be prepared by treating a 1,1 - dialkyl - 1 - ethynylcarbanol with cuprous chloride and HCl in the presence of copperbronze powder and calcium chloride. The pharmaceutically acceptable acid addition salts of the compounds of Formula I are prepared by reacting the free base with an appropriate acid.
The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
Preserving liver function is vital, especially after hepatectomy, the main curative treatment of liver tumor. An hepatectomy that preserved a remnant liver volume \< 0.5% of the body weight is associated with a very high risk of post-operative liver failure. In such situation, liver volume is not sufficient to support local hemodynamic consequences of the hepatectomy that is responsible of intrahepatic endothelial cell injury that impaired liver function and regeneration. To date, preoperative vein embolization (PVE) associated or not to liver transection (ALPSS procedure) that increased future remnant liver from 20% to 90% is the only method to prevent this complication. Even this preparation is necessary for the moment, PVE increased cancer cell proliferation and is associated with lower recurrence free survival than without PVE. Despite a potential PVE, POLF occurred in 5% to 7% after major hepatectomy and stayed the first cause of death after hepatectomy. It has been demonstrated that portal pressure superior to 20 mm Hg and/or porto-caval gradient superior to 12 mm Hg at the end of hepatectomy was associated to the occurrence of POLF. Aim to avoid this acute intra hepatic portal hypertension associated to major hepatectomy that is associated with an early liver endothelial cell injury, we had developed an silicon ring to dispose around the portal vein that contained an circular inflatable balloon to narrow precisely the portal vein lumen (MID-AVRTM).

Phase A: Tolerance and functionality of MID-AVR during surgery Each procedure will be filmed. Phase B: Tolerance and functionality of MID-AVR after surgery Each procedure will be filmed.
The application model will be 3 months of treatment with monthly interval between sessions, totaling 3 sessions. The parameters are as follows: frequency 15 J / cm2, pulse duration 15 ms, 1-2 passed as erythema. Eye protection for IPL will be used during all sessions.
The invention relates to a traditional Chinese medicine composition for diminishing inflammation and relieving pain, which is prepared from the following raw material medicines: chinese angelica, eucommia bark, szechuan lovage rhizome, fortune's drynaria rhizome, cibotium barometz, Chinese taxillus twig, teasel root, medicinal cyathula root, costus root, cassia twig, dahurian angelica root, baical skullcap root, amur corktree bark, corydalis tuber and clematis root. The invention also provides the application of the traditional Chinese medicine composition. Its advantages are: the traditional Chinese medicine composition of the invention supplements each other, accords with the theory of traditional Chinese medicine, and can effectively diminish inflammation and relieve pain. The functional indications are as follows: relaxing muscles and tendons, promoting blood circulation, relieving inflammation, and alleviating pain. Can be used for treating acute and chronic injury, joint pain, and lumbar muscle strain. The traditional Chinese medicine composition disclosed by the invention is proved by tests to be capable of obviously improving the pain threshold of mice and has obvious curative effects on acute soft tissue injury, chronic soft tissue injury, knee joint pain and lumbar muscle strain.
BACKGROUND: Over recent decades, a growing body of evidence has emerged linking the composition of the gut microbiota to sleep regulation. Interestingly, the prevalence of sleep disorders is commonly related to cardiometabolic comorbidities such as diabetes, impaired lipid metabolism, and metabolic syndrome (MetS). In this complex scenario, the role of the gut-brain axis as the main communicating pathway between gut microbiota and sleep regulation pathways in the brain reveals some common host-microbial biomarkers in both sleep disturbances and MetS. As the biological mechanisms behind this complex interacting network of neuroendocrine, immune, and metabolic pathways are not fully understood yet, the present systematic review aims to describe common microbial features between these two unrelated chronic conditions.
RESULTS: This systematic review highlights a total of 36 articles associating the gut microbial signature with MetS or sleep disorders. Specific emphasis is given to studies evaluating the effect of dietary patterns, dietary supplementation, and probiotics on MetS or sleep disturbances.
CONCLUSIONS: Dietary choices promote microbial composition and metabolites, causing both the amelioration and impairment of MetS and sleep homeostasis.
<P>PROBLEM TO BE SOLVED: To provide an IL-6 signal transmission-antagonizing peptide.  <P>SOLUTION: The peptide which inhibits signal transmission by binding a ligand to a receptor for controlling vital reactions and recognizes the three-dimensional structure of the molecule has been obtained from a random peptide library having a cysteine residue at the N-terminal side and totally comprising 35 residues by an in vitro virus method which is an evolutionary engineering means. Tests for obtaining a functional peptide high in specificity and affinity from enormous libraries have been performed to find a homologous peptide. Especially, it has been found that the functions of the peptide by a method of cysteine residues forming two or more S-S bonds and S-S cross-links thereof are largely changed. The peptide is an IL-6 signal transmission-antagonizing peptide having a function for binding to the receptor of IL-6 to inhibit the bonding of IL-6 to IL-6 receptor.  <P>COPYRIGHT: (C)2008,JPO&INPIT
A multi-label classification method for generating labels annotated on medical images. An initial dataset including medical images and partial input labels is obtained. The partial input labels annotate a labeled part of abnormal features on the medical images. A first multi-label classification model is trained with the initial dataset. Difficulty levels of the medical images in the initial dataset are estimated based on predictions generated by the first multi-label classification model. The initial dataset is divided based on the difficulty levels of the medical images into different subsets. A second multi-label classification model is trained based on subsets with gradually increasing difficulty levels during different curriculum learning rounds. Predicted labels annotated on the medical images are generated about each of the abnormal features based on the second multi-label classification model.
Eighty-four overweight pediatric subjects will be enrolled sequentially and randomized 2:1 in experimental and control groups for six months of weight management programming. The experimental group and their parents/guardians will participate in ten weekly 2-hour sessions, comprised of 1 hour of exergaming or exergaming combined with traditional exercise and 1 hour of didactic classes focusing on nutrition and psychosocial behaviors related to weight management. Following these 10 weeks, they will attend monthly 1-hour maintenance didactic classes. The control group and their parents/guardians will participate only in the didactic portion of the curricula for the same duration of time, 10 weeks, followed by monthly maintenance classes for the remainder of the 6 month period. The control group will then be offered participation in the Exergaming for Health program upon study completion.

Comparisons between the two groups will be obtained through changes in the measurements of weight, height, BMI z-scores, shuttle run times, and responses to questionnaires about screen time, self-perception, and nutrition. Measurements of both groups will be obtained at baseline and 6 months and another set of measurements will be obtained on the experimental group at 12 months.
BACKGROUND: It is unclear witch regimen is optimal as salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) monotherapy for recurrent or metastatic head and neck cancer (RM-HNC).
METHODS: This study enrolled 109 patients. Overall survival (OS) and progression-free survival 2 (PFS2) were compared between patients stratified by SCT regimen.
RESULTS: Of the 109 patients, 55 underwent SCT after the failure of ICI monotherapy. The OS of these 55 patients was longer than that of patients who did not undergo SCT. The OS and PFS2 were similar between patients treated with paclitaxel (PTX) and cetuximab (Cmab) combination and those treated with PTX monotherapy. The occurrence of irAEs did not impact PFS2 nor OS.
CONCLUSIONS: SCT can improve the survival outcomes of patients with RM-HNC. In addition to PTX and Cmab, PTX monotherapy is also considered an effective SCT regimen. SCT is effective regardless of the presence or absence of irAEs.
Liraglutide + open-label Metformin. Liraglutide will be titrated to the maximum dose tolerated (up to 1.8 mg/day) after which metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).